Plasma circulating cell free messenger RNA as a potential biomarker of melanoma-Reference-Cited by-同舟云学术

Plasma circulating cell free messenger RNA as a potential biomarker of melanoma

Published:2021-06-04 Issue:9 Volume:60 Page:1201-1209
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Ita Michael Itak¹²^ORCID,Wang Jiang Huai¹,Fanning Noel³,Kaar George²,Lim Chris²,Redmond Henry Paul¹

Affiliation:

1. Department of Academic Surgery, University College Cork, Cork, Ireland

2. Department of Neurosurgery, University College Cork, Cork, Ireland

3. Department of Radiology, University College Cork, Cork, Ireland

Publisher

Informa UK Limited

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2021.1928749

Reference26 articles.

1. Clinical and prognostic factors for melanoma of the skin using SEER registries: Collaborative stage data collection system, version 1 and version 2

2. National Cancer Registry Ireland. Essential Information on Cancer in Ireland. Melanoma Skin | C43 in Ireland 1994-2015 (all ages). Available from: https://www.ncri.ie/data/incidence-statistics

3. null

4. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Comprehensive Review on Circulating cfRNA in Plasma: Implications for Disease Diagnosis and Beyond;Diagnostics;2024-05-17

2. Immunotherapy in melanoma: Can we predict response to treatment with circulating biomarkers?;Pharmacology & Therapeutics;2024-04

3. Integrated analysis of circulating cell free nucleic acids for cancer genotyping and immune phenotyping of tumor microenvironment;Frontiers in Genetics;2023-04-06

4. CDCA3 is a prognostic biomarker for cutaneous melanoma and is connected with immune infiltration;Frontiers in Oncology;2023-01-11

5. Apprising Diagnostic and Prognostic Biomarkers in Cutaneous Melanoma—Persistent Updating;Journal of Personalized Medicine;2022-09-14